Clinical Research Papers:

Gene expression analysis of head and neck squamous cell carcinoma survival and recurrence

Xu Zhi, Katarzyna Lamperska, Paweł Golusinski, Nicholas J. Schork, Lukasz Luczewski, Tomasz Kolenda, Wojciech Golusinski and Michal M. Masternak _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:547-555. https://doi.org/10.18632/oncotarget.2772

Metrics: PDF 2188 views  |   HTML 2882 views  |   ?  


Xu Zhi1,2, Katarzyna Lamperska3, Paweł Golusinski4,6, Nicholas J. Schork5, Lukasz Luczewski6, Tomasz Kolenda3,7, Wojciech Golusinski6 and Michal M. Masternak2,6

1 Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Peking University Third Hospital, Beijing, China

2 College of Medicine, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, USA

3 Deptartment of Cancer Genetics, Greater Poland Cancer Centre, Poznan, Poland

4 Department of Enviromental Biology, Poznan University of Medical Sciences, Poznan, Poland

5 Human Biology, The J. Craig Venter Institute, La Jolla, CA, USA

6 Department of Head and Neck Surgery, Greater Poland Cancer Centre, Poznan University of Medical Sciences, Poznan, Poland

7 Postgraduate School of Molecular Medicine, Medical University of Warsaw, Poland


Michal M. Masternak, email:

Keywords: PCR array, cancer pathway, gene expression, oral cancer

Received: August 28, 2014 Accepted: November 15, 2014 Published: November 16, 2014


The squamous cell carcinomas represent about 90 % of all head and neck cancers, ranking the sixth most common human cancer. Approximately 450,000 of new cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed every year. Unfortunately, because of diagnosis at the advanced stages and early metastasis to the lymph nodes, the HNSCC is associated with very high death rate. Identification of signature biomarkers and molecularly targeted therapies could provide more effective and specific cancer treatment, prevent recurrence, and increase survival rate. We used paired tumor and adjacent normal tissue samples to screen with RT² Profiler™ PCR Array Human Cancer PathwayFinderTM . Total of 20 up-regulated genes and two down-regulated genes were screened out. Out of 22 genes, 12 genes were subsequently validated to be significantly altered in the HNSCC; the samples were from all 41 patients. Five year survival and recurrence selected genes that could represent the biomarkers of survival and recurrence of the disease. We believe that comprehensive understanding of the unique genetic characteristics of HNSCC could provide novel diagnostic biomarkers and meet the requirement for molecular-targeted therapy for the HNSCC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2772